Suven Life Sciences Ltd, a Hyderabad based biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, announced that the company has received four  product patents, one from Europe (EP 1948166), one from New Zealand (566495), one from Australia (200431229) and one from Korea (1016972) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases and these patents are valid through 2025.

The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and schizophrenia.

With these new patents, Suven has a total of eight granted patents from Europe, ten granted patents from New Zealand, nine granted patents from Australia and three  granted from Korea for the NCEs. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at phase-I or phase-II.

“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders which has an estimated $30 billion market potential globally,” said Venkat Jasti, CEO of Suven.